{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:05:12Z","timestamp":1780517112032,"version":"3.54.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cpet.2026.02.002","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:11:27Z","timestamp":1775560287000},"page":"383-392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer \u2013 Current State and Evolving Standards"],"prefix":"10.1016","volume":"21","author":[{"given":"Swayamjeet","family":"Satapathy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal R.","family":"Chandekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishikant A.","family":"Damle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpet.2026.02.002_bib1","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cpet.2026.02.002_bib2","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpet.2026.02.002_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262311665","article-title":"Therapeutic advances in metastatic prostate cancer: a journey from standard of care to new emerging treatment","volume":"26","author":"Cicchetti","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cpet.2026.02.002_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101450","article-title":"Advances in PSMA theranostics","volume":"22","author":"Jeitner","year":"2022","journal-title":"Transl Oncol"},{"key":"10.1016\/j.cpet.2026.02.002_bib5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-Y","article-title":"Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues","volume":"1","author":"Wright","year":"1995","journal-title":"Urol Oncol"},{"key":"10.1016\/j.cpet.2026.02.002_bib6","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s12149-024-01957-x","article-title":"Physiological biodistribution on Ga68-PSMA PET\/CT and the factors effecting biodistribution","volume":"38","author":"Ar\u00e7ay \u00d6zt\u00fcrk","year":"2024","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.cpet.2026.02.002_bib7","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2967\/jnumed.119.233411","article-title":"Radiation dosimetry in 177Lu-PSMA-617 Therapy Using a Single uosttreatment SPECT\/CT scan: a novel methodology to generate time- and tissue-specific dose factors","volume":"61","author":"Jackson","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cpet.2026.02.002_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115966","article-title":"A systematic review on the current status of PSMA-targeted imaging and radioligand therapy","volume":"263","author":"Capasso","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.cpet.2026.02.002_bib9","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cpet.2026.02.002_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2967\/jnumed.121.263262","article-title":"Appropriate use criteria for prostate-specific membrane antigen PET Imaging","volume":"63","author":"Jadvar","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cpet.2026.02.002_bib11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/jmrs.227","article-title":"Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy","volume":"64","author":"Emmett","year":"2017","journal-title":"J Med Radiat Sci"},{"key":"10.1016\/j.cpet.2026.02.002_bib12","first-page":"79","article-title":"Long-Term nephrotoxicity of 177Lu-PSMA Radioligand Therapy","volume":"65","author":"Steinhelfer","year":"2024","journal-title":"J NucltMed"},{"key":"10.1016\/j.cpet.2026.02.002_bib13","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","article-title":"PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cpet.2026.02.002_bib14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cpet.2026.02.002_bib15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2026.02.002_bib16","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cpet.2026.02.002_bib17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2026.02.002_bib18","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpet.2026.02.002_bib19","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/pros.24325","article-title":"177 Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: an updated systematic review and meta-analysis","volume":"82","author":"Sadaghiani","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.cpet.2026.02.002_bib20","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.2967\/jnumed.123.265414","article-title":"[177Lu]Lu-PSMA-radioligand therapy efficacy outcomes in taxane-na\u00efve versus taxane-treated patients with metastatic castration-resistant prostate cancer: a systematic review and metaanalysis","volume":"64","author":"Satapathy","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cpet.2026.02.002_bib21","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1007\/s00259-021-05618-3","article-title":"177Lu-PSMA-617 versus docetaxel in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial","volume":"49","author":"Satapathy","year":"2022","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.cpet.2026.02.002_bib22","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.2967\/jnumed.123.266141","article-title":"[177Lu]Lu-PSMA-617 versus docetaxel in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: final survival analysis of a phase 2 randomized, controlled trial","volume":"64","author":"Satapathy","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cpet.2026.02.002_bib23","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cpet.2026.02.002_bib24","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.annonc.2025.07.003","article-title":"Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer","volume":"36","author":"Fizazi","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cpet.2026.02.002_bib25","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s00259-024-06677-y","article-title":"[177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study","volume":"51","author":"Satapathy","year":"2024","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.cpet.2026.02.002_bib26","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.eururo.2021.06.012","article-title":"Short-course 177Lu-PSMA-617 radioligand therapy in high-volume metastatic hormone-sensitive prostate cancer: time to take the leap?","volume":"80","author":"Satapathy","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.cpet.2026.02.002_bib27","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1158\/1078-0432.CCR-20-4298","article-title":"Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer: a prospective pilot study","volume":"27","author":"Priv\u00e9","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2026.02.002_bib28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/RLU.0000000000005000","article-title":"Promising therapeutic activity of 177Lu-PSMA-617 in synchronous high-volume metastatic hormone-sensitive prostate cancer : a pilot experience","volume":"49","author":"Satapathy","year":"2024","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.cpet.2026.02.002_bib29","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2026.02.002_bib30","first-page":"1068","article-title":"177Lu-PSMA-617 consolidation therapy after docetaxel in patients with synchronous high-volume metastatic hormone-sensitive prostate cancer: a randomized, phase 2 trial","volume":"66","author":"Satapathy","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cpet.2026.02.002_bib31","doi-asserted-by":"crossref","first-page":"S1742","DOI":"10.1016\/j.annonc.2025.09.101","article-title":"LBA6 phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)","volume":"36","author":"Tagawa","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cpet.2026.02.002_bib32","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41391-021-00349-w","article-title":"Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer-a systematic review and meta-analysis","volume":"24","author":"Satapathy","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.cpet.2026.02.002_bib33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2026.02.002_bib34","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4103\/ijnm.IJNM_130_20","article-title":"Health-related quality-of-life outcomes with Actinium-225-prostate-specific membrane antigen-617 therapy in patients with heavily pretreated metastatic castration-resistant prostate cancer","volume":"35","author":"Satapathy","year":"2020","journal-title":"Indian J Nucl Med"},{"key":"10.1016\/j.cpet.2026.02.002_bib35","first-page":"e466","article-title":"Delayed nephrotoxicity after 225Ac-PSMA-617 Radioligand Therapy","volume":"47","author":"Satapathy","year":"2022","journal-title":"Clin Ntcl Med"},{"key":"10.1016\/j.cpet.2026.02.002_bib36","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(25)00332-8","article-title":"First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1\/2 study","volume":"26","author":"Buteau","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2026.02.002_bib37","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2026.02.002_bib38","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1470-2045(25)00009-9","article-title":"Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2026.02.002_bib39","doi-asserted-by":"crossref","first-page":"S1300","DOI":"10.1016\/j.annonc.2025.08.3007","article-title":"2391P LuPARP: phase I trial of [177Lu]Lu-PSMA-617 (LuPSMA) and olaparib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)","volume":"36","author":"Sandhu","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cpet.2026.02.002_bib40","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","article-title":"Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2026.02.002_bib41","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S1470-2045(25)00559-5","article-title":"Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1\/2 trial","volume":"26","author":"Kostos","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2026.02.002_bib42","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-01553","article-title":"177Lu-prostate-specific membrane antigen neoadjuvant to stereotactic ablative radiotherapy for oligorecurrent prostate cancer (LUNAR): an open-label, randomized, controlled, phase ii study","author":"Kishan","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpet.2026.02.002_bib43","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2026.02.002_bib44","article-title":"Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","author":"Yanagisawa","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.cpet.2026.02.002_bib45","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/RLU.0000000000003307","article-title":"Visceral metastases as predictors of response and survival outcomes in patients of castration-resistant prostate cancer treated with 177Lu-labeled prostate-specific membrane antigen radioligand therapy: a systematic review and meta-analysis","volume":"45","author":"Satapathy","year":"2020","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.cpet.2026.02.002_bib46","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1038\/s41591-025-03704-9","article-title":"Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial","volume":"31","author":"Kwan","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.cpet.2026.02.002_bib47","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2026.02.002_bib48","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233460","article-title":"Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION trial)","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.cpet.2026.02.002_bib49","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.2967\/jnumed.123.266167","article-title":"Prediction of resistance to 177Lu-PSMA therapy by assessment of baseline circulating tumor DNA biomarkers","volume":"64","author":"Sartor","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cpet.2026.02.002_bib50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41391-021-00424-2","article-title":"Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer","volume":"25","author":"Priv\u00e9","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.cpet.2026.02.002_bib51","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/pros.24450","article-title":"Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: a single-center experience","volume":"83","author":"Satapathy","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/j.cpet.2026.02.002_bib52","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2967\/jnumed.123.265448","article-title":"Renal and multiorgan safety of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer in the VISION dosimetry substudy","volume":"65","author":"Herrmann","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cpet.2026.02.002_bib53","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2967\/jnumed.118.219352","article-title":"Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes","volume":"60","author":"Violet","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cpet.2026.02.002_bib54","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/pros.24549","article-title":"PSMA-heterogeneity in metastatic castration-resistant prostate cancer: circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy","volume":"83","author":"Derlin","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/j.cpet.2026.02.002_bib55","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2967\/jnumed.124.268640","article-title":"Therapy-related myeloid neoplasms after [177Lu]Lu-PSMA therapy in patients with metastatic castration-resistant prostate cancer: a case series","volume":"66","author":"Eifer","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cpet.2026.02.002_bib56","first-page":"1851","article-title":"Challenges with 177Lu-PSMA-617 radiopharmaceutical therapy in clinical practice","volume":"65","author":"Jadvar","year":"2024","journal-title":"J Nucl Med"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859826000209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859826000209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:39:08Z","timestamp":1780515548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859826000209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1556859826000209"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2026.02.002","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer \u2013 Current State and Evolving Standards","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2026.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}